Skip navigation
  LIVE QUOTE
Quotes delayed 15+ min.

Current DateTime: 06:15:36 10 Feb 2012
LinksList Documentid: 23452764
Expiration DateTime: 2/10/2012 6:18:24 AM

Current DateTime: 06:15:38 10 Feb 2012
LinksList Documentid: 23452000
Expiration DateTime: 2/10/2012 6:18:40 AM

Current DateTime: 06:15:43 10 Feb 2012
LinksList Documentid: 24355697

Feds accuse Wyeth of cheating Medicaid

By: The Associated Press | 18 May 2009 | 05:58 PM ET
Text Size
Allege hundreds of millions unpaid in scam using stomach medicine

WASHINGTON - The Justice Department on Monday accused Wyeth, one of the nation’s biggest drugmakers, of cheating Medicaid programs out of hundreds of millions of dollars by overcharging for a stomach acid drug.

The Justice Department and more than a dozen states have joined in two whistleblower lawsuits against the Madison, N.J.-based drug company filed in federal court in Massachusetts.

The court papers claim that between 2000 and 2006, Wyeth offered steep discounts to thousands of hospitals for two versions of Protonix, a drug that suppresses stomach acid.

By law, manufacturers of brand-name drugs are required to offer the same rebates to state Medicaid programs that they provide to other customers.

The government claims the maneuver helped the company avoid paying hundreds of millions of dollars in rebates to Medicaid, a health care program for the poor that is funded by state and federal money.

“By offering massive discounts to hospitals, but then hiding that information from the Medicaid program, we believe Wyeth caused Medicaid programs throughout the country to pay much more for these drugs than they should have,” Assistant Attorney General Tony West said in a statement.

In court papers, the government accused the drug company of bundling the intravenous version of Protonix with the oral version in sales packages to hospitals, in the hopes of making more money in the lucrative outpatient market.

Wyeth defended its pricing plan.

“The company believes that it’s pricing calculations were correct and intends to defend itself vigorously in these actions,” said Doug Petkus, a Wyeth spokesman.

The states joining the lawsuit are California, Delaware, Florida, Illinois, Indiana, Louisiana, Massachusetts, New York, Michigan, Nevada, New Hampshire, Tennessee, Texas, Virginia and Wisconsin, as well as the District of Columbia.

New York-based drugmaker Pfizer Inc. is in the process of acquiring Wyeth for more than $60 billion in a deal expected to close later this year.

Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Tools:
Add This share icon

CNBC HIGHLIGHTS

  • How much did the Facebook founder pay for other shareholders' voting rights? Not a heck of a lot, says the NY Times.
  • Here’s a look at Westminster Kennel Club’s most successful breeds and how much they cost.
  • The oft-mentioned jobs "miracle" in European economic powerhouse Germany has a dark side that's largely escaped comment.
  • Job Interview
  • When looking for that next career move,  workers need to look at the differences between a start-up and a public firm.
  • After enduring the recession, many Baby Boomers say money isn’t the most important thing they hope to leave to their kids.
  • The ‘Fast Money’ traders weigh in on fashion related stocks from apparel to footwear to accessories and fragrances.


Current DateTime: 05:18:53 10 Feb 2012
LinksList Documentid: 29778428

Current DateTime: 04:15:11 10 Feb 2012
LinksList Documentid: 29779196

Current DateTime: 04:16:05 10 Feb 2012
LinksList Documentid: 29779197

Current DateTime: 04:16:04 10 Feb 2012
LinksList Documentid: 29779199
CNBCCNBC
About CNBC  |  Site Map  |  Video Reprints   |  Advertise  |  Help  |  Contact
Privacy Policy  |     |  Terms of Service  |  Independent Programming Report
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2012 CNBC LLC.  All Rights Reserved.
A Division of NBCUniversal
Thomson ReutersThomson Reuters